| 1 |
Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006;113:1807-16.
DOI
|
| 2 |
Felker GM, Shaw LK, O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 2002;39:210-8.
|
| 3 |
Tenenbaum A, Fisman EZ, Motro M. Toward a redefinition of ischemic cardiomyopathy: is it an indivisible entity? J Am Coll Cardiol 2002;40:205-6.
|
| 4 |
Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011;364:1617-25.
DOI
|
| 5 |
Kim EK, Chang SA, Choi JO, et al. Concordant and discordant cardiac magnetic resonance imaging delayed hyperenhancement patterns in patients with ischemic and non-ischemic cardiomyopathy. Korean Circ J 2016;46:41-47.
DOI
|
| 6 |
Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006;48:1977-85.
DOI
|
| 7 |
Alter P, Rupp H, Adams P, et al. Occurrence of late gadolinium enhancement is associated with increased left ventricular wall stress and mass in patients with non-ischaemic dilated cardiomyopathy. Eur J Heart Fail 2011;13:937-44.
DOI
|
| 8 |
Unverferth DV, Baker PB, Swift SE, et al. Extent of myocardial fibrosis and cellular hypertrophy in dilated cardiomyopathy. Am J Cardiol 1986;57:816-20.
DOI
|
| 9 |
Burch GE, Giles TD, Colcolough HL. Ischemic cardiomyopathy. Am Heart J 1970;79:291-2.
DOI
|
| 10 |
Atkinson JB, Virmani R. Congestive heart failure due to coronary artery disease without myocardial infarction: clinicopathologic description of an unusual cardiomyopathy. Hum Pathol 1989;20:1155-62.
DOI
|
webmaster
